2′-O Methylation of the Viral mRNA Cap by West Nile Virus Evades Ifit1-Dependent and -Independent Mechanisms of Host Restriction In Vivo by Szretter, Kristy J. et al.
29-O Methylation of the Viral mRNA Cap by West Nile
Virus Evades Ifit1-Dependent and -Independent
Mechanisms of Host Restriction In Vivo
Kristy J. Szretter
1, Brian P. Daniels
2, Hyelim Cho
3, Maria D. Gainey
1, Wayne M. Yokoyama
1,4,
Michael Gale Jr.
5, Herbert W. Virgin
3,4, Robyn S. Klein
1,2,4, Ganes C. Sen
6, Michael S. Diamond
1,3,4*
1Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United Stated of America, 2Department of Anatomy & Neurobiology,
Washington University School of Medicine, St. Louis, Missouri, United Stated of America, 3Department of Molecular Microbiology, Washington University School of
Medicine, St. Louis, Missouri, United Stated of America, 4Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, United
Stated of America, 5Department of Immunology, University of Washington School of Medicine, Seattle, Washington, United States of America, 6Cleveland Clinic, Lerner
Research Institute, Cleveland, Ohio, United States of America
Abstract
Prior studies have shown that 29-O methyltransferase activity of flaviviruses, coronaviruses, and poxviruses promotes viral
evasion of Ifit1, an interferon-stimulated innate immune effector protein. Viruses lacking 29-O methyltransferase activity
exhibited attenuation in primary macrophages that was rescued in cells lacking Ifit1 gene expression. Here, we examined
the role of Ifit1 in restricting pathogenesis in vivo of wild type WNV (WNV-WT) and a mutant in the NS5 gene (WNV-E218A)
lacking 29-O methylation of the 59 viral RNA cap. While deletion of Ifit1 had marginal effects on WNV-WT pathogenesis,
WNV-E218A showed increased replication in peripheral tissues of Ifit1
2/2 mice after subcutaneous infection, yet this failed
to correlate with enhanced infection in the brain or lethality. In comparison, WNV-E218A was virulent after intracranial
infection as judged by increased infection in different regions of the central nervous system (CNS) and a greater than
16,000-fold decrease in LD50 values in Ifit1
2/2 compared to wild type mice. Ex vivo infection experiments revealed cell-type
specific differences in the ability of an Ifit1 deficiency to complement the replication defect of WNV-E218A. In particular,
WNV-E218A infection was impaired in both wild type and Ifit1
2/2 brain microvascular endothelial cells, which are believed
to participate in blood-brain barrier (BBB) regulation of virus entry into the CNS. A deficiency of Ifit1 also was associated with
increased neuronal death in vivo, which was both cell-intrinsic and mediated by immunopathogenic CD8
+ T cells. Our
results suggest that virulent strains of WNV have largely evaded the antiviral effects of Ifit1, and viral mutants lacking 29-O
methylation are controlled in vivo by Ifit1-dependent and -independent mechanisms in different cell types.
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Introduction
Type I interferon(IFN)restrictsinfectionofmany virusesthrough
cell-intrinsic and cell-extrinsic effects on replication, and by priming
adaptive B and T cell responses (reviewed in [1]). Expression of type
I IFN after RNA virus infection generally occurs after recognition of
viral RNA by pathogen recognition receptors in the cytoplasm (by
RIG-I and MDA5) or the endosome (TLR3, TLR7, and TLR8),
and initiation of signaling cascades that result in translocation of
interferon regulatory factors (IRF-3 and IRF-7) with transcriptional
activity (reviewed in [2]). Secreted type I IFN binds to the IFN-ab
receptor (IFNAR) in autocrine and paracrine fashion, activating the
Janus kinase and signal transducer and activator of transcription
(JAK/STAT) pathway, whichinduces the expressionofhundredsof
interferon stimulated genes (ISG) with the potential for antiviral
function against a range of viruses [3].
Ifit1 (ISG56, p56) is a highly induced ISG with tetratricopeptide
repeats, and a member of an evolutionarily conserved family of
proteins that are expressed in response to type I IFN, interleukin-1
(IL-1), tumor necrosis factor alpha (TNF-a) and certain pathogen
associated molecular patterns (PAMPs) (reviewed in [4]). In
humans, the IFIT gene family consists of four members: IFIT1,
IFIT2 (ISG54, p54), IFIT3 (ISG60, p60), and IFIT5 (ISG58, p58),
whereas mice encode three related genes: Ifit1, Ifit2, and Ifit3
(ISG49, p49); human IFIT1 and mouse Ifit1 show 53% sequence
identity at the amino acid level. Infection and replication of DNA
and RNA viruses are potent inducers of Ifit family gene expression
in many cell types [5–7]. Initial studies suggested that human IFIT
proteins exerted their antiviral function by inhibiting protein
translation through interaction with specific subunits of translation
initiation factor eIF3 [8–13]. More recent studies have suggested
additional inhibitory mechanisms including the control of trans-
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of the 59 cap [14,15], sequestration of specific viral RNA,
including 59-ppp RNA [16], and direct binding and inhibition of
viral proteins [17]. In cell culture, human and mouse IFIT1/Ifit1
reportedly have antiviral activity against several viruses including
human papilloma, Sindbis, vesicular stomatitis, and hepatitis C
viruses [13,16,18–20]. In cell culture and mouse models of
infection, WNV strongly induces Ifit1 gene expression in target
cells via IFN-dependent and -independent signaling pathways
[6,7].
West Nile Virus (WNV) is an enveloped, single-stranded positive
sense RNA virus in the Flaviviridae family and an emerging cause of
epidemic encephalitis worldwide [21]. Following peripheral
infection, WNV replication is thought to occur in subsets of
dendritic cells. These cells migrate to and seed draining lymph
nodes, resulting in viremia and subsequent infection of visceral
organs such as the spleen. By the end of the first week, WNV is
largely cleared from peripheral tissues and spreads to the CNS
with infection and injury of neurons in the cerebral cortex,
hippocampus, brain stem, and spinal cord. Although the exact
entry route of WNV into the CNS remains unclear, it has been
proposed to enter via retrograde axonal transport from peripheral
neurons [22], direct infection of brain microvascular endothelial
cells [23], inflammation-induced disruption of BBB integrity [24–
26], or trafficking of virus-infected leukocytes [27,28].
We and others have described a WNV mutant with a site-
specific substitution in the NS5 gene (WNV-E218A) that abolishes
29-O-methyltransferase activity [29] and attenuates infection in
wild type mice and cells [14]; replication of WNV-E218A in
primary macrophages, however, was rescued in the absence of
IFNAR or Ifit1 [14]. Here, we follow-up on these studies by
examining the role of Ifit1 in restricting pathogenesis in vivo of wild
type WNV (WNV-WT) and WNV-E218A. While Ifit1 had a
marginal impact on WNV-WT pathogenesis, replication of WNV-
E218A was increased in peripheral tissues of Ifit1
2/2 mice after
subcutaneous infection, yet this failed to result in efficient spread to
the brain. In contrast, direct introduction of WNV-E218A into the
brain of Ifit1
2/2 mice was associated with rapid infection of
neurons resulting in uniform lethality. Ex vivo infection experi-
ments revealed cell-type specific differences in the ability of Ifit1
deficiency to rescue the replication defect of WNV-E218A. Our
results suggest that viral mutants lacking 29-O methylation are
controlled in vivo by Ifit1-dependent and -independent mecha-
nisms.
Results
WNV-E218A shows enhanced replication but not
virulence in Ifit1
2/2 mice after peripheral infection
To determine the significance of Ifit1 in restricting WNV
infection, and the role of 29-O methylation in this process, we
assessed WNV infection of Ifit1
2/2 mice. We obtained Ifit1
2/2
C57BL/6 embryonic stem (ES) cells from the trans-NIH Knock-
Out Mouse Project (KOMP) consortium and generated mice with
a targeted deletion; cells derived from these mice lacked expression
of Ifit1 yet induced normal levels of Ifit2 (Figure S1 and S2). We
challenged eight week-old wild type and Ifit1
2/2 mice via a
subcutaneous route with 10
2 PFU of a virulent strain of WNV-NY
(derived from the 385-99 infectious clone; New York, 1999) and
compared this to survival after infection with WNV-E218A, a
recombinant virus generated from the parent infectious clone with
a point mutation in NS5 that abolishes its 29-O methyltransferase
activity [14,29]. Ifit1
2/2 mice infected with WNV-WT showed a
trend towards increased mortality, although this failed to attain
statistical significance (52% survival for Ifit1
2/2 mice compared to
75% survival for wild type mice, P=0.1; Figure 1A); thus, in
contrast to previous results with other ISGs [30,31], an absence of
Ifit1 did not markedly enhance pathogenesis of the virulent North
American WNV strain. As seen previously [14], the WNV-E218A
variant lacking 29-O methylation of its viral RNA cap was highly
attenuated in wild type mice, as neither morbidity nor mortality
was observed. Somewhat surprisingly, given its rescue in Ifit1
2/2
macrophages, the WNV-E218A mutant remained attenuated in
Ifit1
2/2 mice, as no disease was observed after subcutaneous
infection with 10
2 or 10
5 PFU of virus or after infection of younger
more vulnerable five week-old mice (Figure 1A, and data not
shown). This suggests that mechanisms beyond Ifit1-mediated
control also contribute to the attenuation of WNV lacking 29-O
methylation.
To begin to understand why an absence of Ifit1 failed to
enhance virulence of WNV, mice were infected with WNV-WT or
WNV-E218A and viral burden was examined at different days
after infection in serum, peripheral organs (spleen and kidney) and
the brain. Consistent with the lack of a significant mortality
phenotype in Ifit1
2/2 mice, WNV-WT accumulated to equivalent
levels in the blood, spleen, and brain of wild type and Ifit1
2/2
mice (P.0.2), with the exception of a slight (2.7-fold) increase
(P=0.04) in serum at day 3 in Ifit1
2/2 mice (Figure 1B, C, and
D). Moreover, a deficiency in Ifit1 did not result in productive
infection of the kidney (Figure 1E), an organ that is normally
resistant to WNV infection in wild type mice yet permissive in
animals with defects in type I IFN induction, signaling, or effector
functions [31–35]. In comparison, despite the absence of mortality
after subcutaneous inoculation, WNV-E218A showed enhanced
peripheral infection in Ifit1
2/2 mice and accumulated in the
serum and spleen to comparable levels observed in wild type mice
infected with WNV-WT (P,0.05, comparison of WNV-E218A
between wild type and Ifit1
2/2 mice; Figure 1B and C). So why
did WNV-E218A fail to cause mortality after subcutaneous
infection? Viral burden analysis in the brain revealed markedly
lower (14 to 448-fold, P,0.01) titers in the brains of wild type and
Author Summary
We recently showed that a West Nile virus (WNV) mutant in
NS5 (WNV-E218A) lacking 29-O methyltransferase activity
was attenuated in primary macrophages but replicated
well in cells lacking type I interferon (IFN) signaling or
expression of Ifit1, an IFN-stimulated gene. Here, we
follow-up these studies by examining the pathogenesis in
Ifit1
2/2 mice of WNV-E218A, the mutant virus lacking 29-O
methyltransferase activity. Because a deficiency of Ifit1 did
not alter pathogenesis of wild type WNV, we conclude that
the viral 29-O methyltransferase encoded by NS5 largely
overcomes Ifit1-mediated control of infection. In compar-
ison, WNV-E218A showed increased infection in peripheral
tissues of Ifit1
2/2 mice after subcutaneous infection, yet
this did not result in enhanced replication in the brain.
However, WNV-E218A caused lethal infection when it was
directly introduced into the brain. We observed cell-type
specific differences in the ability of an Ifit1 deficiency to
rescue replication of WNV-E218A; for example, WNV-E218A
showed equivalently impaired infection in wild type and
Ifit1
2/2 brain endothelial cells, which potentially allow
virus access into the brain. Our results suggest that virulent
strains of WNV have evaded the antiviral effects of Ifit1,
and mutants lacking 29-O methylation are restricted by
cell-type specific Ifit1-dependent and -independent mech-
anisms.
Pathogenesis of West Nile Virus in Ifit12/2 Mice
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2/2 mice infected with WNV-E218A at days 6, 8, and 10 after
infection (Figure 1D). Thus, an absence of Ifit1 largely restored
infection of the 29-O methylation mutant WNV in peripheral
tissues but this was not associated with complementation of
replication defects in the brain, likely explaining the attenuated
disease phenotype of the WNV-E218A mutant in Ifit1
2/2 mice.
A deficiency of Ifit1 rescues virulence of WNV-E218A in
the CNS
As the subcutaneous infection experiments suggested tissue
specific restriction of WNV-E218A by Ifit1, we hypothesized that
the 29-O methylation mutant might replicate less efficiently in the
central nervous system (CNS), which would explain the attenuated
phenotype. To begin to address this, we performed a lethal dose
(LD50) analysis after intracranial infection of WNV-E218A in wild
type and Ifit1
2/2 mice. While the intracranial infection model is
not directly relevant to WNV disease pathogenesis, it allows for
examination of viral infection in neurons directly and bypasses
barriers associated with neuroinvasion. Notably, in wild type mice,
the LD50 of WNV-E218A was greater than 10
5 PFU, as no
lethality was observed at even the highest dose tested (Figure 2).
Remarkably, in Ifit1
2/2 mice, the virulence of WNV-E218A was
restored via the intracranial route with an LD50 of 6 PFU
(,16,600-fold lower). In comparison, no appreciable difference of
LD50 for WNV-WT was observed between wild type and Ifit1
2/2
mice (4 versus 6 PFU, data not shown). Thus, the defect in
neurovirulence in Ifit1
2/2 mice that was observed after peripheral
infection of WNV-E218A was not due to an inherent inability of
the 29-O methylation mutant virus to cause disease in the brain.
To extend these findings, we performed plaque assays on tissue
homogenates isolated from different regions of the central nervous
system (CNS). Wild type and Ifit1
2/2 mice were infected with
WNV-E218A directly into the brain via an intracranial route and
viral burden in the cerebral cortex, sub-cortex, brain stem,
cerebellum, and spinal cord was measured on days 2, 4, 6, and 8
after infection. At day 2 after intracranial infection, higher WNV-
E218A titers were measured in the cortex (35-fold, P=0.0002),
sub-cortex (28-fold, P,0.0001), brain stem (7-fold, P=0.0009),
and cerebellum (31-fold, P=0.0003) in Ifit1
2/2 mice compared to
wild type mice (Figure 3A, B, C, and D). Analogously, higher
levels of virus (5 to 38-fold (P,0.02)) were measured in these brain
regions at day 4 after infection. By day 6, however, no difference in
viral burden was detected in cortex, brainstem and cerebellum
(P.0.09), although WNV-E218A was 3-fold higher (P=0.008) in
the sub-cortex and 6-fold higher (P=0.005) in the spinal cord of
ifit1
2/2 mice (Figure 3E). These results demonstrate that a
deficiency of Ifit1 enhanced the ability of WNV-E218A to
replicate and spread in CNS tissues. Importantly, virus harvested
Figure 1. Survival and viral burden analysis after subcutaneous infection of wild type and Ifit1
2/2 C57BL/6 mice. A. Nine week-old wild
type (n=20) and Ifit1
2/2 (n=25) mice were inoculated subcutaneously with WNV-NY (10
2 PFU, solid lines) or WNV-E218A (10
5 PFU, dotted lines) and
mice were monitored for mortality over 21 days. (B–D) WNV tissue burden and spread in mice after subcutaneous infection. Ifit1
2/2 and wild type
mice were infected with WNV-WT or WNV-E218A via subcutaneous injection in the footpad. At the indicated times post infection, tissues were
harvested and analyzed for viral burden by quantitative RT-PCR (B) or plaque assay (C–E). Data is shown as WNV genome equivalents per 50 mlo f
serum or PFU per gram of tissue for 10 to 15 mice per time point. Error bars represent standard error of the mean and dotted lines indicate the limit
of detection of the assays. Asterisks indicate values that are statistically significant between wild type and ifit1
2/2 mice (*, P,0.05; ***, P,0.0005).
doi:10.1371/journal.ppat.1002698.g001
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2/2 mice at day 6 retained the WNV-
E218A mutation as judged by direct sequencing of plaque-purified
isolates (data not shown).
While pathogenesis in the CNS was restored when WNV-
E218A was directly inoculated into the brain of Ifit1
2/2 mice, this
virus still replicated to relatively high titer in the brains of wild type
mice yet failed to induce lethality. To investigate the disparity
between the absence of a lethality phenotype and high viral
burden data in wild type mice, we assessed WNV-E218A
replication on day 8 after intracranial infection, a day by which
all ifit1
2/2 mice had succumbed to infection. While WNV-E218A
replicated to high levels in most regions of the CNS on day 6, we
observed a rapid clearance phase with 3 to 36-fold reduced viral
titers (P,0.05) on day 8 in wild type mice (Figure 3A, B, C, and
D).
Ifit1 restricts replication of WNV lacking 29-O methylation
in subsets of primary cells
Given the viral replication phenotype in vivo, we hypothesized
that Ifit1 differentially mediated antiviral actions within specific
cell types. To evaluate this, we compared multi-step growth
kinetics of WNV-WT and WNV-E218A in several wild type and
Ifit1
2/2 primary cells including fibroblasts (MEF), dendritic cells
(DC), and neurons from the neocortex (cortical neurons, CN) or
hindbrain (cerebellar granular cell neurons, GCN). Initial studies
established that none of the primary cells deficient in Ifit1
sustained enhanced infection with WNV-WT compared to wild
type cells (Figure 4A–D, P.0.1) at any of the time points
examined. In comparison, WNV-E218A replicated less efficiently
(4 to 19-fold, P,0.05) than WNV-WT in wild type MEF, DC,
CN, and GCN (Figure 4A–D). This defect was partially restored
in Ifit1
2/2 DC (5.2-fold increase, P,0.001), CN (4-fold increase at
72 hours, P,0.001), and GCN (6.1-fold increase, P,0.003) but
not substantially altered in MEF. These experiments suggest that
flavivirus mutants lacking 29-O methylation are growth inhibited to
varying degrees in distinct primary cells, and this occurs through
Ifit1-dependent and independent mechanisms. The cell type-
specific differences, however, were not due to variation in
induction of Ifit1, as the gene was expressed highly in all cells
after viral infection (Figure S2).
A deficiency of Ifit1 fails to restore WNV-E218A
replication in brain endothelial cells
While WNV-E218A replicated in the brains of Ifit1
2/2 mice
after direct intracranial inoculation, it failed to sustain high-level
infection in the CNS or cause lethality following subcutaneous
inoculation, despite achieving near normal titers in the serum and
spleen. We hypothesized that WNV-E218A in particular, might
have impaired neuroinvasive potential, which was not rescued by a
deficiency in Ifit1. Brain microvascular endothelial cells (BMEC)
have been hypothesized to participate in the entry of WNV into
the CNS, possibly through direct infection or altered barrier
functions secondary to systemic inflammation [23–26]. To assess
whether WNV-E218A had defects in infection of endothelial cells,
multi-step viral growth kinetics were performed in BMEC derived
from wild type and Ifit1
2/2 mice. Notably, WNV-WT replicated
to significantly higher levels (6 to 20-fold at 48 and 72 hours,
P,0.02) than WNV-E218A in wild type BMEC, and this
difference was not complemented by a deficiency of Ifit1
(Figure 3F); thus, WNV-E218A showed a growth defect in
BMEC independent of Ifit1 expression. In comparison, we
observed no difference or significant levels of positive strand viral
RNA in blood leukocytes at days 3 after infection of WNV-WT or
WNV-E218A in Ifit1
2/2 mice (data not shown). Moreover, no
differences in accumulation of intravascular proinflammatory
cytokines (IL1-b, IL-6, IFN-c, and TNF-a) were observed in
Ifit1
2/2 mice infected with WNV-WT or WNV-E218A at days 3
and 4 (Figure S3, and data not shown), time points that are
believed critical for cytokine-induced modulation of BBB perme-
ability [26]. These observations suggest that the attenuated clinical
phenotype of WNV-E218A after subcutaneous infection of wild
type or Ifit1
2/2 mice may be attributed in part to its inability to
efficiently infect CNS endothelial cells.
An absence of Ifit1 leads to immune- and virus-induced
pathology after intracranial infection with WNV-E218A
To further understand the clinical phenotype of WNV-E218A
in Ifit1
2/2 mice after intracranial infection, we assessed inflam-
matory cell accumulation in the brains. At day 6 after intracranial
infection with WNV-E218A, leukocytes were isolated from brains
of wild type and ifit1
2/2 mice and analyzed by flow cytometry.
Notably, higher numbers of activated CD11b
high CD45
low
microglia (2-fold, Figure 5A, P=0.005), CD3
+CD4
+ T cells (2-
fold, Figure 5B, P=0.0009), and CD3
+CD8
+ T cells (4-fold,
Figure 2. Ifit1
2/2 mice are more susceptible to WNV-E218A
infection by an intracranial inoculation. Nine week-old wild type
(n=4 to 10 per dose) and Ifit1
2/2 (n=5 to 10 per dose) mice were
inoculated via an intracranial route with serial 10-fold dilutions of WNV-
E218A and monitored for 21 days for mortality. The P values for specific
comparisons of mortality are indicated.
doi:10.1371/journal.ppat.1002698.g002
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2/2
mice, although no difference in the number of CD11b
high
CD45
high macrophages was observed (Figure 5A, P.0.4). The
CD8
+ T cell response in the brain was WNV-specific, as higher
numbers of cells expressing IFN-c (4-fold, Figure 5C, P,0.0001),
TNF-a (3-fold, Figure 5C, P,0.0001), or granzyme B (4-fold,
Figure 5C, P,0.0001) were detected after ex vivo restimulation
with a D
b-restricted WNV NS4B peptide [36], and elevated
Figure 3. WNV-E218A replication in regions of the CNS of Ifit1
2/2 mice after intracranial infection. (A–E) Ifit1
2/2 or wild type mice were
infected with 10
5 PFU of WNV-E218A via intracranial injection. At the indicated times after infection, (A) cerebral cortex, (B) sub-cortex, (C) brain
stem, (D) cerebellum, and (E) spinal cord were harvested and analyzed for viral burden by plaque assay on BHK21-15 cells. Data is shown as PFU per
gram of tissue from 8 to 11 mice per time point. (F) Wild type or Ifit1
2/2 BMEC were infected at an MOI of 0.01 with WNV-WT or WNV-E218A, and
virus yield was titrated at the indicated times by focus forming assay. Values are an average of triplicate samples generated from three independent
experiments. Solid lines represent the median viral titer, error bars represent the standard error of the mean, and dotted lines indicate the limit of
detection of the respective assays. Asterisks indicate values that are statistically significant between wild type and Ifit1
2/2 mice (*, P,0.05;
**, P,0.005; ***, P,0.0005).
doi:10.1371/journal.ppat.1002698.g003
Figure 4. Ifit1 restricts viruses lacking 29-O methylation of the viral mRNA cap infection in some but not all primary cells. (A) MEF and
(C) CN were generated from embryos of wild type and Ifit1
2/2mice, (D) GCN were generated from neonatal wild type and Ifit1
2/2mice, and (B)D C
were derived from bone marrow of adult wild type and Ifit1
2/2mice. Primary cells were infected with (A–D) WNV-WT and WNV-E218A at an MOI of
0.01 and virus yield was titrated at the indicated times by focus forming assay on Vero cells. Values are an average of triplicate samples generated
from at least three independent experiments. The dotted line represents the limit of detection for the assay. Statistically significant differences are
described in the text of the Results.
doi:10.1371/journal.ppat.1002698.g004
Pathogenesis of West Nile Virus in Ifit12/2 Mice
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b-NS4B tetramer-positive cells also were measured
(4-fold, Figure 5C, P,0.0001). These results confirm that wild
type mice mount a robust cellular immune response to WNV-
E218A, which likely contributes to viral clearance observed at day
8 (see Figure 3). In comparison, a deficiency of Ifit1 was
associated with increased infection by WNV-E218A, which likely
secondarily resulted in enhanced recruitment of lymphocytes to
the CNS. This response in Ifit1
2/2 mice nonetheless failed to
control infection and/or contributed to lethality by inducing
immunopathology.
Lethality from neurotropic viruses, such as WNV can be
attributed to both cell-intrinsic and cell-extrinsic mechanisms
[37,38]. We speculated that part of the clinical phenotype after
intracranial infection of WNV-E218A in Ifit1
2/2 mice was due to
accelerated neuronal death. To address this idea using an in vitro
model, we assessed the effect of Ifit1 on WNV-induced cell death
in CN. CN from wild type and Ifit1
2/2 mice were infected (MOI
of 0.01) with WNV-WT or WNV-E218A, and cell viability was
assessed initially by measuring levels of intracellular ATP. At 48
and 72 hours after infection, Ifit1
2/2 CN infected with WNV-WT
showed lower viability compared to wild type CN (48 hours:
83.4% viable wild type cells versus 73.3% viable Ifit1
2/2 cells,
P,0.0001; and 72 hours: 58.8% viable wild type cells versus
45.2% viable Ifit1
2/2 cells, P,0.0001) (Figure 6A); this effect,
however, was not associated with differences in viral replication
between wild type and Ifit1
2/2 CN (see Figure 4C). In
comparison, Ifit1
2/2 CN infected with WNV-E218A showed
slightly decreased viability at 48 hours (94.8% in Ifit1
2/2 CN
versus 98.4% in wild type CN, P=0.005) and significantly lower
viability at 72 hours (61.4% in Ifit1
2/2 CN versus 96.4% in wild
type CN, P,0.0001) (Figure 6A), although part of this phenotype
may be explained by the 4-fold increase in replication in CN at
72 hours (see Figure 4C). Consistent with these results, in
confocal microscopy experiments with WNV-E218A-infected
primary CN, we observed enhanced TUNEL staining in Ifit1
2/2
compared to wild type cells at 48 and 72 hours despite similar
levels of viral antigen (Figure 6B). While some cells co-stained for
TUNEL and WNV antigen (white arrows), the majority of TUNEL-
positive neurons appeared negative for WNV antigen yet were in
proximity to clusters of infected cells (yellow arrowheads). Although
more investigation is warranted, these neurons may have
undergone cell death after WNV infection and leaked cytoplasmic
viral antigen or were injured in a bystander fashion from
excitotoxic amino acids, peptides, or proteins [39] that were
released by adjacently infected cells.
To assess whether a corresponding phenotype was observed in
vivo, we stained fixed frozen sections from brains of wild type and
Ifit1
2/2 mice infected via the intracranial route with WNV-E218A
for qualitative and quantitative analysis of cell death via TUNEL
assay. At day 6 after infection, a time point when relatively similar
amounts of infectious virus was detected in several regions of the
brain of wild type and Ifit1
2/2 mice (see Figure 3), we observed
markedly increased numbers of TUNEL-positive neurons in the
cerebral cortex (Figure 6C, and 6D: i versus 6D: v, P=0.02)
and hippocampus (Figure 6C, and 6D: ii versus 6D: vi,
P=0.04) of Ifit1
2/2 mice, although this pattern was not seen in
the brain stem (Figure 6C, and 6D: iii versus 6D: vii)o r
cerebellum (Figure 6C, and 6D: iv versus 6D: viii). Analysis of
adjacent sections that were co-stained for WNV antigen showed
similar findings, with an increased number of TUNEL-positive
cells in Ifit1
2/2 mice in the background of similar number of
WNV-E218A-infected cells (Figure 6E: i–viii). Again, and
analogous to results with primary CN (Figure 6B), there was a
noticeable disparity in TUNEL-positive and WNV-positive cells.
Overall, subsets of Ifit1
2/2 neurons appear more susceptible to
WNV-E218A infection and cell death in culture and in vivo.
To address whether infiltrating cytotoxic T lymphocytes
independently contributed to the lethality phenotype in Ifit1
2/2
mice infected with WNV-E218A, we administered a CD8-b-
depleting antibody (H35 clone, rat IgG2b) or isotype control to
Ifit1
2/2 mice by peripheral injection one day prior to challenge of
mice with WNV-E218A via an intracranial route. Although all
Ifit1
2/2 mice succumbed to infection regardless of treatment,
depletion of CD8
+ T cells delayed the mean time to death by 3
days (P,0.001, Figure 7A and B), suggesting a pathologic effect
of these cells in Ifit1
2/2 mice. In comparison, no deleterious
clinical effect was observed after CD8
+ T cell depletion of wild
type mice infected with WNV-E218A (data not shown). To
corroborate these results, we depleted CD8
+ T cells immediately
prior to infection of wild type or Ifit1
2/2 mice with WNV-E218A,
prepared frozen sections from different brain regions at day 6, and
quantitated the number of TUNEL-positive cells by confocal
microscopy. Consistent with the survival data, depletion of CD8
+
T cells reduced the number of TUNEL-positive neurons in the
cerebral cortex, brain stem, and cerebellum of Ifit1
2/2 mice
(P,0.02, Figure 7C and D). Nonetheless, there was a limit to the
Figure 5. Leukocyte accumulation in the CNS after WNV-E218A infection by an intracranial route. Wild type and Ifit1
2/2 mice were
inoculated with 10
5 PFU of WNV-E218A by intracranial injection. (A–C) Brains were harvested on day 6 after infection, and leukocytes were isolated
by percoll gradient centrifugation. The total number of (A) microglia (CD11b
high/CD45
low) and macrophages (CD11b
high/CD45
high), or (B) CD3
+CD4
+
or CD3
+CD8
+ T cells was determined by multiplying the percentage of each cell population by the total cell count. (C) Brain leukocytes were stained
with a D
b-NS4b tetramer or stimulated ex vivo with a D
b-restricted NS4B WNV peptide and then stained for CD3, CD8, granzyme B, IFN-c or TNF-a,
and analyzed by flow cytometry. Data represent the average of at least two independent experiments with 4 to 7 mice per experiment (n=8 to 14).
Asterisks indicate values that are statistically significant between wild type and Ifit1
2/2 mice (**, P,0.005; ***, P,0.0005).
doi:10.1371/journal.ppat.1002698.g005
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PLoS Pathogens | www.plospathogens.org 7 May 2012 | Volume 8 | Issue 5 | e1002698protective effects of CD8
+ T cell depletion, as additional doses of
the H35 antibody failed to prolong survival beyond that observed
with a single dose (Figure 7A). These data confirm that CD8
+ T
cells have the potential to cause immunopathology associated with
WNV infection in the brain [40], and suggest that the accelerated
neuronal injury observed in Ifit1
2/2 mice after WNV-E218A
infection is caused in part, by CD8
+ T cells.
Discussion
Here, we generated Ifit1
2/2 mice and established the role of
Ifit1 protein in restricting pathogenesis of wild type WNV and a
mutant (NS5-E218A) lacking 29-O methyation of the 59 cap of its
viral RNA. For the virulent wild type strain of WNV, a deficiency
of Ifit1 had little impact on infectivity or pathogenesis, as no
significant increase in lethality, tissue viral burden, or replication
in primary cells was observed. Thus, Ifit1 does not have a
dominant role in restricting infection or pathogenesis of wild type
WNV, which is consistent with the hypothesis that 29-O
methylation of the 59 viral RNA cap by the viral methyltransferase
(NS5) effectively subverts innate host antiviral responses through
escape of Ifit1-mediated suppression [14]. In comparison, a
deficiency of Ifit1 enhanced the virulence of the attenuated
WNV-E218A mutant lacking 29-O-methyation. While infection of
wild type mice with WNV-E218A via the subcutaneous route
resulted in little apparent disease even with doses up to 10
5 PFU,
Ifit1
2/2 mice showed enhanced susceptibility to WNV-E218A
with elevated viral burden in serum and spleen, although this
Figure 6. Ifit1 protects against neuronal death during WNV infection. (A) CN were infected at an MOI 0.01 with WNV-WT or WNV-E218A and
cell viability evaluated at indicated times using a CellTiter-Glo commercial assay. Data represents the percentage of viable cells normalized to mock-
infected neurons at each time point. (B) CN were seeded on coverslips and infected at an MOI 0.01 with WNV-E218A. At the indicated time points,
coverslips were fixed and co-stained for WNV antigen (green), TUNEL (red) and the nuclear stain ToPro-3 (blue). Representative images of ten high-
powered fields from at least three separate coverslips are shown. (C–E) Wild type and Ifit1
2/2 mice were infected with 10
5 PFU of WNV-E218A via
intracranial injection. At day 6, tissues were harvested and processed as described in the Methods. (C) The number of TUNEL-positive cells was
quantified from three high-powered fields per brain region per mouse from four independent mice. Fixed, frozen section from the (D: i and v)
cerebral cortex, (D: ii and vi) hippocampus, (D: iii and vii) brain stem, and (D: iv and viii) cerebellum were co-stained for the MAP-2 neuronal
antigen (green), TUNEL (red) and the nuclear stain ToPro-3 (blue). Fixed, frozen section from the (E: i and v) cerebral cortex, (E: ii and vi)
hippocampus, (E: iii and vii) brain stem, and (E: iv and viii) cerebellum were co-stained for the WNV antigen (green), TUNEL (red) and the nuclear
stain ToPro-3 (blue). Images are representative of 4 to 6 mice. White arrows indicate TUNEL-positive neurons, yellow arrowheads indicate TUNEL-
positive and WNV antigen-positive cells and bars indicate 20 mM. Asterisks indicate values that are statistically significant between wild type and
Ifit1
2/2 mice (*, P,0.05; **, P,0.005, ***, P,0.0001).
doi:10.1371/journal.ppat.1002698.g006
Figure 7. CD8
+ T cells are pathogenic following WNV-E218A infection. Nine week-old Ifit1
2/2 (n=6 to 12) mice were injected via
intraperitoneal route with 450 mg of H35 CD8b-depleting antibody or an isotype control one day prior to intracranial inoculation with 10
5 PFU of
WNV-E218A. A subset of mice received a second dose of antibody on day 5 after infection. (A) Survival was monitored daily. The difference in mean
time to death was statistically significant between isotype and H35 MAb treated Ifit1
2/2 mice (P,0.0001). (B) Representative dot plots illustrating
depletion of CD8
+ T cells in the brains of Ifit1
2/2 mice after H35 MAb administration. (C) At day 6, tissues were harvested and processed as described
in the Methods. Fixed, frozen sections were co-stained for the MAP-2 neuronal antigen (green), TUNEL (red) and the nuclear stain ToPro-3 (blue). The
number of TUNEL-positive cells was quantified from three high-powered fields per brain region per mouse from four independent mice. Asterisks
indicate values that are statistically significant between H35 MAb and isotype control antibody treated Ifit1
2/2 mice (*, P,0.05; **, P,0.005). (D)
Representative images of the cerebral cortex and cerebellum from H35 MAb or isotype control antibody treated Ifit1
2/2 mice. White arrows indicate
TUNEL-positive neurons, and bars indicate 20 mM.
doi:10.1371/journal.ppat.1002698.g007
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disease. Ex vivo infection experiments revealed impaired infectivity
of WNV-E218A in both wild type and Ifit1
2/2 BMEC, which are
a major component of the BBB and are hypothesized to contribute
to WNV entry into the CNS [23]. Thus, the failure of WNV-
E218A to spread to the brain after peripheral inoculation could be
due in part, to an Ifit1-independent restriction in BBB infection
and virus crossing.
Although Ifit1 is highly expressed in multiple areas of the brain
after WNV infection [7], and is thus in position to restrict infection
of WNV-E218A, the attenuated phenotype after peripheral
infection of Ifit1
2/2 mice still could have been due to an intrinsic
inability to replicate in target neurons of the CNS. Against this,
direct inoculation of WNV-E218A into the brain in Ifit1
2/2 mice
resulted in enhanced replication, inflammation, and neuronal
injury, which resulted in lethal infection with an LD50 of 6 PFU; in
comparison, no lethality was observed in wild type mice after
direct intracranial inoculation of even high (10
5 PFU) doses of
WNV-E218A, although high levels (10
5 to 10
7 PFU/g) of virus
accumulated in multiple regions of the brain. Our studies suggest
that lethal phenotype after WNV-E218A infection by the
intracranial route in Ifit1
2/2 mice was due to both cell-intrinsic
and extrinsic mechanisms. WNV-infected Ifit1
2/2 CN were less
viable following infection in vitro, and the increased viral burden in
the brain elicited greater numbers of infiltrating lymphocytes,
including CD8
+ T cells that appeared to contribute to pathogen-
esis by WNV-E218A. Taken together, our results show that viral
mutants lacking 29-O methylation are controlled in vivo in part, by
Ifit1-dependent mechanisms, and suggest a possible route for
WNV neuroinvasion in the CNS.
Our ex vivo infection experiments revealed cell-type specific
differences in the ability of a deficiency of Ifit1 to rescue the
replication defect of WNV-E218A. In prior studies, we showed
that Ifit1
2/2 but not Ifit2
2/2 macrophages supported almost wild
type levels of replication of flaviviruses (WNV-E218A) and
coronaviruses (mouse hepatitis virus (MHV)-D130A) lacking 29-
O methylation of the viral RNA cap [14,15]. Here, we observed a
range of Ifit1-dependent and -independent phenotypes for
restricting replication of WNV-E218A; in no instance, however,
did we observe an increase in replication of WNV-WT in any of
the Ifit1
2/2 primary cells examined. Whereas Ifit1
2/2 DC and
GCN sustained enhanced infection of WNV-E218A, Ifit1
2/2
MEF and CN showed smaller increases in infection, and as
mentioned above, no increase in WNV-E218A replication was
observed in Ifit1
2/2 BMEC. A similar pattern was observed with
the MHV-D130A 29-O methylation mutant virus, as Ifit1
2/2
GCN and DC supported enhanced replication but Ifit1
2/2 CN
did not (K. Szretter and M. Diamond, unpublished results). Thus,
our cell culture data suggests that viruses lacking 29-O methylation
are restricted in a cell-type specific manner by Ifit1-dependent and
-independent mechanisms. While a prior study with MHV
suggested that viruses lacking 29-O methylation also may be
recognized preferentially by the RNA sensor MDA5 [15] resulting
in enhanced type I IFN secretion, we did not observe this
phenotype with WNV-E218A; we saw no significant restoration in
infectivity of WNV-E218A in several different Mda5
2/2 primary
cells and no rescue of virulence in Mda5
2/2 mice (H. Lazear and
M. Diamond, unpublished results). Thus, the identity and
biochemical basis of the Ifit1-independent control pathway against
WNV-E218A remains unknown, although other gene family
members (mouse Ifit2 or Ifit3) are candidates under study.
Despite its robust induction after viral infection or exposure of
cells to type I IFN [41–43], Ifit1 did not contribute significantly to
the control of wild type WNV infection in vivo. Similarly, we
observed no difference in clinical phenotype between wild type
and Ifit1
2/2 mice after infection with encephalomyocarditis
(EMCV), a picornavirus that has a viral protein (VPg) covalently
bound to the 59 end of its positive-strand genomic RNA (V.
Fensterl and G. Sen, unpublished results). These results were
somewhat surprising, as Ifit1 has been proposed to have antiviral
functions beyond its capacity to inhibit infection of viruses lacking
29-O-methylation of the viral mRNA cap. Human or mouse Ifit1
reportedly have antiviral activity in cell culture against human
papilloma, Sindbis, Rift valley fever, and hepatitis C viruses
[13,16,18–20], and in vivo against vesicular stomatitis virus [16].
While initial studies suggested that Ifit proteins exerted their
antiviral function by inhibiting protein translation [8–13],
additional inhibitory mechanisms have been proposed including
sequestration of viral RNA replication intermediates, including 59-
ppp RNA [16], and direct binding and inhibition of viral proteins
[17]. While WNV and other flaviviruses have capped genomes at
the 59 end of the infectious positive RNA strand, in theory, Ifit1
could recognize other viral derived RNA with free 59-ppp
including the negative strand RNA replicative intermediate or
sfRNA [44,45]. However, our results showing little difference in
replication phenotype for WNV-WT in Ifit1
2/2 mice and cells
suggest that recognition of 59-ppp RNA is not critical for host
control of WNV. Alternatively, a gain-of-function phenotype may
not have been observed in Ifit1
2/2 mice after WNV-WT infection
because multiple ISG function in concert to inhibit viral
replication in vivo, such that targeted deletion of a single gene
(e.g. Ifit1) with relatively modest effects results in a minimal
phenotype. Indeed, cell culture studies have shown that several
different ISG have inhibitory activity against a given family of
viruses [3,19,46].
The BBB poses a physical obstacle for pathogen entry into the
brain through its endothelial cell tight junctions and astrocyte foot
processes. Although the exact route of WNV entry into the CNS
remains unclear, WNV may enter via axonal spread [22], direct
infection of endothelial cells [23], inflammation-induced disrup-
tion of BBB integrity [24–26] or possibly through transport within
trafficking hematopoietic cells, such as neutrophils [28]. Our
peripheral and intracranial infection studies with WNV-E218A in
Ifit1
2/2 mice are more consistent with a model in which direct
infection of endothelial cells contributes to CNS spread. However,
by immunohistochemistry we did not detect WNV antigen in
brain endothelial cell from wild type or Ifit1
2/2 mice (K. Szretter
and M. Diamond, unpublished results); this could reflect the
,100-fold lower level of virus accumulation in BMEC relative to
neurons, which may fall below the limit of current histological
detection methods. Although WNV-E218A readily infected
neurons after direct intracranial infection of Ifit1
2/2 mice, little
replication in the brain was observed after subcutaneous
inoculation despite relatively normal levels of viremia, and this
finding correlated with an Ifit1-independent mechanism of control
in BMEC ex vivo. We also cannot exclude the possibility of a
transient difference in BBB permeability of Ifit1
2/2 mice induced
specifically by peripheral infection of WNV-WT but not WNV-
E218A. Indeed, a recent study suggested that Ifit1 may act a
negative regulator of virus-triggered cellular antiviral responses
through its binding to STING and disruption of interaction with
IPS-1 and TBK1 [47]; Ifit1
2/2 mice after peripheral infection of
WNV-WT and WNV-E218A should therefore have increased
inflammation compared to wild type mice. However, we failed to
observe significant differences in pro-inflammatory cytokine
production in wild type and Ifit1
2/2 mice after WNV infection.
While we did observe increased inflammatory infiltrates in the
brains of Ifit1
2/2 mice infected with WNV-E218A via an
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virus replication in neurons, which induces chemokine production
that facilitates leukocyte infiltration [48,49].
An absence of Ifit1 was associated with increased neuronal
injury and death in vivo and this likely occurred through both cell-
intrinsic and cell-extrinsic mechanisms. Infection experiments in
primary CN showed that cell viability was compromised more
rapidly in Ifit1
2/2 compared to wild type cells after WNV-WT or
WNV-E218A infection, despite relatively equivalent levels of viral
production in the supernatant. The mechanistic basis for this
remains uncertain although a recent study suggested that
expression of IFIT2 modulates apoptosis [50]. In vivo, after
intracranial infection of WNV-E218A, we observed significantly
more TUNEL-positive neurons in Ifit1
2/2 compared to wild type
mice, and this occurred in a region-specific manner. While some of
this phenotype was likely due to the enhanced virus replication in
Ifit1
2/2 mice, depletion of CD8
+ T cells resulted in prolonged
survival, suggesting a contribution of immune cell mediated injury.
While prior studies have defined a protective role for CD8
+ T cells
after peripheral infection by virulent strains of WNV [36,51–53],
our findings with WNV-E218A are more consistent with a report
showing immunopathogenic CD8
+ T cells after infection with an
attenuated WNV strain [40]. Likely, for virulent strains of WNV,
CD8
+ T cell-dependent injury of a relatively small number of
infected neurons outweighs the risk of widespread cell death
induced directly by the virus.
In summary, our results show that Ifit1 restricts infection in vivo
of WNV lacking 29-O methylation of the 59 cap structure, as
targeted Ifit1 gene deletion was associated with enhanced
replication of WNV-E218A in mice. Because a deficiency of Ifit1
did not significantly alter pathogenesis of WNV-WT, we conclude
that 29-O methylation of the 59 viral RNA cap by the NS5 largely
overcomes Ifit1-mediated restriction of infection. Based on tissue
and region-specific effects in vivo, and infection of primary cells ex
vivo, we postulate a model in which distinct cell types differentially
use Ifit1 to inhibit infection of WNV-E218A, and likely other
viruses, lacking 29-O methylation. However, the viral NS5 29-O
methyltransferase enzyme also effectively antagonizes this Ifit1-
independent pathway. Studies are underway to define additional
ISGs (e.g., Ifit2, Ifit3 or others) that explain Ifit1-independent
control of WNV-E218A in vivo, and the precise cellular and
biochemical antiviral mechanism(s) of action.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee at the Washington University School of Medicine
(Assurance Number: A3381-01). All inoculation and experimental
manipulation was performed under anesthesia that was induced
and maintained with ketamine hydrochloride and xylazine, and all
efforts were made to minimize suffering.
Virus propagation and titration
WNV-WT and WNV-E218A were generated from an
infectious cDNA clone of the New York 1999 strain and
propagated in C6/36 Aedes albopictus or BHK21-15 cells as
described [14,54]. BHK21-15 and Vero cells were used to
measure viral titers of infected cells or tissues by plaque or focus-
forming assays [55,56]. Viremia was determined by measuring
viral RNA levels in serum using quantitative real-time reverse
transcriptase polymerase chain reaction (qRT-PCR) and previ-
ously defined primer sets [55].
Mouse experiments and tissue preparation
Wild type C57BL/6 mice were obtained commercially (Jackson
Laboratories, Bar Harbor, ME). Congenic Ifit1
2/2 mice were
generated from C57BL/6 embryonic stem cells that were
produced by the trans-NIH Knock-Out Mouse Project and
obtained from their repository (www.komp.org). Ifit1
2/2 ES cells
were microinjected into (Cg)-Tyr
c-2J/J albino C57BL/6 mice
recipient female mice. Chimeric mice with black coat color were
selected and bred to wild type C57BL/6. Homozygous Ifit1
2/2
mice were generated by intercrossing the heterozygous animals
and confirmed by PCR. Ifit1
2/2 mice were fertile and exhibited
normal Mendelian frequencies.
Eight to ten week-old age-matched wild type or Ifit1
2/2 mice
were inoculated with specified doses of WNV-WT or WNV-
E218A diluted in Hanks balanced salt solution (HBSS) supple-
mented with 1% heat-inactivated fetal bovine serum (FBS) either
by footpad (10
2 to 10
5 PFU in 50 ml) or intracranial injection (10
1
to 10
5 PFU in 10 ml). On specific days after infection, mice were
sacrificed and extensively perfused with iced phosphate buffered
saline (PBS), and organs were harvested, weighed, and stored at
280uC until further processing. Alternatively, groups of mice were
monitored for twenty-one days after infection for survival.
Primary cell infection
Primary bone marrow-derived DC, MEF, CN and GCN from
wild type and Ifit1
2/2 mice were generated as described [57,58].
Primary BMEC were prepared as described [59,60] with some
modifications. Eight week-old Ifit1
2/2 and congenic wild type
C57BL/6 mice were sacrificed followed by dissection of cerebral
cortices and removal of meninges. Cerebral cortical tissue was
digested in 1 mg/ml type 2 collagenase (Worthington) and 30 U/
ml DNase (Sigma-Aldrich) with shaking for 60 minutes at 37uC.
Digested blood vessels were separated from myelinated cortical
cells by centrifugation in a 20% BSA solution in DMEM (1,0006
g) for 20 minutes. Isolated vessels were digested in 1 mg/ml
collagenase-dispase (Roche) and 10 U/ml DNase with shaking for
45 minutes at 37uC. BMEC were then isolated by centrifugation
on a 33% continuous Percoll gradient with 3% FBS (1,0006g) for
10 minutes, washed twice with DMEM, and plated in T-25 flasks
coated with 0.1 mg/ml mouse collagen type IV (Sigma-Aldrich)
and 0.1 mg/ml human fibronectin (Sigma-Aldrich). Multi-step
virus growth curves were performed after infection at a multiplicity
of infection (MOI) of 0.01. Cell viability of virus-infected cells was
measured using Cell Titer-Glo Luminescent Cell Viability assay
(Promega) according to the manufacturer’s instructions.
CNS leukocyte isolation and phenotyping
Quantification of infiltrating CNS lymphocytes was based on a
published protocol [61]. Briefly, wild type and Ifit1
2/2 mouse
brains were harvested on day 6 after intracranial inoculation,
minced, and digested with 0.05% collagenase D, 0.1 mg/ml
trypsin inhibitor TLCK, and 10 mg/ml DNase I in HBSS
supplemented with 10 mM HEPES, pH 7.4 (Life Technologies).
Cells were dispersed into single cell suspensions with a 70 mm cell
strainer and centrifuged through a 37% Percoll cushion for
30 minutes (8506 ga t4 uC). Cells were counted and incubated
with directly conjugated antibodies against CD3, CD4, CD8,
CD45, and CD11b (BD Pharmingen) or D
b-NS4B tetramer (NIH
tetramer core facility). Alternatively, cells were incubated with
5 mg/ml brefeldin A (Sigma) for 6 h at 37uC with 10
26 Mo f
immunodominant T cell peptides (D
b-restricted NS4B 2488–2496
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permeabilized with FixPerm Buffer (eBioscience), and stained
intracellularly for anti-IFN-c (XMG1.2, BD Pharmingen), anti-
TNF-a (MP6-XT22, eBioscience), or anti-granzyme B (GB12,
Invitrogen). Lymphocytes were processed on a Canto II (BD
Bioscience) using FACSDiva 6.1.1 software (BD Bioscience) and
analyzed with FlowJo (Treestar).
Depletion of CD8
+ T cells
Mice were injected via an intraperitoneal route with 450 mgo f
either an anti-CD8-b chain specific monoclonal antibody (H35, rat
IgG2b) or an isotype control (Jackson ImmunoResearch Laborato-
ries). On the following day, mice were challenged via an intracranial
route with 10
5 PFU of WNV-E218A and followed for survival.
Depletion was confirmed three days after administration of the
antibodies by analysis of peripheral blood cells using flow cytometry.
Quantification of mRNA levels by RT-PCR
Total RNA was isolated from primary cells by using the RNeasy
kit according to the manufacturer’s instructions (Qiagen). Follow-
ing DNase I treatment (Invitrogen), cDNA was synthesized using
oligo(dT) random hexamers, and Multiscribe reverse transcriptase
(Applied Biosytems). Reverse transcription was performed using
the following conditions: 25uC for 10 minutes, 48uC for 30 min-
utes, and 95uC for 5 minutes. The following primers were used to
amplify murine Ifit1, Ifit2, and GAPDH mRNA: Ifit1, forward
primer, 59- GCCCTCAGCAGCACAT-
CTTGCCAA -39, reverse primer, 59- CCTGCCTTCTGG-
GCTGCCTGTT -39; Ifit2, forward primer, 59- AAGGACCC-
GAAGAACCCAGAATTCAC -39, reverse primer, 59- GCC-
GGGTACCACATCACTAGTATTCAG -39; and GAPDH, for-
ward primer, 59-GGCAAATTCAACGGCACAGT-39, reverse
primer, 59-AGATGGTGATGGGCTTCCC-39. PCR was per-
formed using Platinum Taq master mix (Invitrogen) after 25 cycles
at 65uC for 15 seconds and 72uC for 30 seconds. PCR products
were analyzed using 2% agarose TAE gel, and imaged using
AlphaEase FC software (Version 3.2.1, Alpha Innotech).
Western blots
Primary cells were lysed in Laemmli buffer (BioRad). Samples
were electrophoresed on 4 to 12% SDS-polyacrylamide gels
(Invitrogen). Following transfer, nitrocellulose membranes were
blocked with 5% nonfat dried milk overnight at 4uC. Membranes
were probed with the rabbit anti-mouse Ifit1 ([7]) and b-actin
(Abcam). Blots were incubated with peroxidase-conjugated
secondary antibodies (Pierce) and visualized using ECL-Plus
Immunoblotting reagents (Amersham Biosciences).
Immunohistochemistry and confocal microscopy
Mice were infected with 10
5 PFU of WNV-E218A via an
intracranial route and sacrificed at day 6 after infection. Following
sequential perfusion with 20 ml PBS and 20 ml 4% paraformal-
dehyde (PFA) in PBS, brains were harvested and fixed in 4% PFA
in PBS overnight at 4uC. Tissues were cryoprotected in 30%
sucrose, embedded, and frozen sections were cut. Tissue
preparation and staining was performed as previously described
[57,61]. After saturating non-specific binding sites and permeabi-
lizing cells, sections were incubated overnight at 4uC with anti-
MAP2 (Chemicon) or anti-WNV (hyperimmune rat sera [62]).
Primary antibodies were detected with secondary Alexa 488- or
Alexa 555-conjugated goat anti-mouse or rat IgG (Molecular
Probes). Nuclei were counter-stained with To-Pro3 (Molecular
Probes). Terminal deoxynucleotidyltransferase-mediated dUTP-
biotin nick end labeling (TUNEL) staining was performed using an
in situ cell death detection kit (Roche) according to the
manufacturer’s instructions, with some modifications [38]. Fluo-
rescence staining was visualized and quantitated with a Zeiss 510
Meta LSM confocal microscope.
Statistical analysis
All data were analyzed using Prism software (GraphPad Prism4).
An unpaired, two-tailed t-test was used to determine statistically
significant differences for in vitro experiments. The Mann-Whitney
test was used to analyze differences in viral burden. Kaplan-Meier
survival curves were analyzed by the log rank test.
Supporting Information
Figure S1 Generation of Ifit1
2/2 mice. A. Gene targeting
strategy for genomic deletion of complete protein-encoding regions
of Ifit1 in embryonic stem cells. The C57BL/6 embryonic stem cells
were produced by the trans-NIH Knock-Out Mouse Project,
obtained from their repository (www.komp.org), and microinjected
into (Cg)-Tyr
c-2J/J albino C57BL/6 mice recipient female mice. B.
A representative image of a gel depicting PCR products from wild
type, heterozygous and Ifit1
2/2 mouse tail DNA.
(TIF)
Figure S2 Expression of Ifit1 in primary cells. MEF and
CN were generated from embryos, GCN were generated from
neonates, macrophages and dendritic cells were derived from bone
marrow,andBMECwerederived from adult wild type and Ifit1
2/2
mice. Primary cells were either mock-treated or treated with 100 IU
of IFN-b for 24 hours, and cell lysates were harvested for RNA or
protein analysis. (A) cDNA was generated from total RNA, PCR
performed for Ifit1, Ifit2, and GAPDH, and products were resolved
by 2% agarose gel electrophoresis. (B) Equivalent amounts of
protein were loaded and separated on a 4–12% PAGE, transferred
to nitrocellulose and blotted for Ifit1 or b-Actin.
(TIF)
Figure S3 Cytokine responses in the serum of WNV-
infected WT and Ifit1
2/2 mice. Nine week-old wild type and
ifit1
2/2 mice were inoculated subcutaneously with 10
5 PFU of
WNV-WT or WNV-E218A. At the indicated times after infection,
serum was harvested and analyzed by Bioplex for IFN-c, IL-1b,
IL-6 and TNF-a. Data is shown as the concentration of cytokine
per mL of serum for 9 to 11 mice per time point. Error bars
represent standard error of the mean and dotted lines indicate the
limit of detection of the assays. On days 3 and 4 after infection,
IFN-c and IL-6 levels were at or below the level of assay detection
in wild type and ifit1
2/2 mice.
(TIF)
Text S1 Supplemental methods.
(DOCX)
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